Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus: revenue of $151.0M beat the $147.0M estimate, driven by a 16% YoY increase in Spatial consumables. However, GAAP net loss of -$17.9M was wider than the anticipated -$1.1M normalized income, and EBIT of -$19.6M missed the -$33.8M estimate (though appears better, the variance stems from non-recurring settlement gains). Q2 gross margin reached 74.5% (calculated), exceeding the 68.9% consensus due to manufacturing efficiencies and one-time tariff refunds.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: 10X Genomics(TXG) the Revenue is 151.04 M (-12.65%), Beat estimate;the EBIT is -19.56 M (-164.9%), Beat estimate;the EPS is -0.14 (--%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.15B12.65%
0.15B15.21%
+0.00B2.56%
EBITExceed expectations
-0.02B164.91%
-0.03B215.85%
+0.02B50.94%
EPSExceed expectations
-0.14--
-0.2471--
+0.1071--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf